Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy
Digestive Diseases and Sciences · 2023
DOI: 10.1007/s10620-023-07916-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2023. Verfasst von Nehna Abdul Majeed und 7 weiteren Autor:innen. Beteiligte Einrichtung: Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis B, Hepatitis C, Hepatitis B, Chronic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Hepatitis B virus (HBV) reactivation has been reported in patients co-infected with hepatitis C virus (HCV) during direct acting antiviral (DAA) therapy, leading the United States Food and Drug Administration (U.S. FDA) to issue a black box warning on all DAA drug labels recommending monitoring for HBV reactivation. We conducted a comprehensive evaluation to assess the rate of HBV reactivation among patients with chronic hepatitis C (CHC) during DAA therapy. METHODS: Patients with CHC and recovered HBV infection (hepatitis B surface antigen negative (HBsAg)/anti-hepatitis B core positive), treated with DAAs were included if stored sera were available. Samples were tested for HBV DNA, HBsAg, and ALT. HBV reactivation was considered if (1) HBV DNA was undetectable pre-DAA therapy and became detectable post-therapy, or (2) HBV DNA was detectable pre-treatment, but not quantifiable (< 20 IU/mL) and became quantifiable post-treatment. RESULT: 79 patients with median age of 62 years were included. 68% were male and Caucasian. Various DAA regimens were administered for 12-24 weeks. Reactivation occurred in 8/79 (10%) of patients and occurred more frequently in men compared to women: 6 during treatment and 2 after treatment. Neither an ALT flare nor HBsAg seroreversion were observed. Detectable HBV DNA was transient in 5/8 and could not be determined in 3/8 but ALT flares were not observed in follow-up of these patients. CONCLUSION: The risk of HBV reactivation was low in CHC patients with resolved HBV during DAA therapy. Our data support testing for HBV DNA only in selected patients with ALT flares or failure of ALT normalization during DAA treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
- Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, Canada.
- Institute of Medical Science, University of Toronto, Toronto, Canada.
- The Toronto Viral Hepatitis Care Network (VIRCAN), Toronto, Canada.
- Department of Gastroenterology, Alta Bates Summit Medical Center, Oakland, CA, USA.
- Transfusion Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
ORCID-Profile: Marc G Ghany
Zitieren
APA
Majeed, N. A., Alawad, A. S., Liem, K. S., Takyar, V., Alter, H., Feld, J. J., Janssen, H. L. A., & Ghany, M. G. (2023). Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-023-07916-2
Vancouver
Majeed NA, Alawad AS, Liem KS, Takyar V, Alter H, Feld JJ, et al. Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy. Digestive Diseases and Sciences. 2023. doi:10.1007/s10620-023-07916-2
BibTeX
@article{Majeed2023,
author = {Majeed, Nehna Abdul and Alawad, Ahmad Samer and Liem, Kin Seng and Takyar, Varun and Alter, Harvey and Feld, Jordan J and Janssen, Harry L A and Ghany, Marc G},
title = {Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy},
journal = {Digestive Diseases and Sciences},
year = {2023},
doi = {10.1007/s10620-023-07916-2}
}
EUVIMED